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In Brief
Declining oocyte quality is considered an
irreversible feature of aging and is rate
limiting for human fertility. Bertoldo et al.
show that reversing an age-dependent
decline in NAD(P)H restores oocyte
quality, embryo development, and
functional fertility in aged mice. These
findings may be relevant to reproductive
medicine.
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https://doi.org/10.1016/j.celrep.2020.01.058SUMMARY
Reproductive aging in female mammals is an irre-
versible process associated with declining oocyte
quality, which is the rate-limiting factor to fertility.
Here, we show that this loss of oocyte quality with
age accompanies declining levels of the prominent
metabolic cofactor nicotinamide adenine dinucleo-
tide (NAD+). Treatment with the NAD+ metabolic
precursor nicotinamide mononucleotide (NMN) reju-
venates oocyte quality in aged animals, leading to
restoration in fertility, and this can be recapitulated
by transgenic overexpression of the NAD+-depen-
dent deacylase SIRT2, though deletion of this
enzyme does not impair oocyte quality. These bene-
fits of NMN extend to the developing embryo, where
supplementation reverses the adverse effect of
maternal age on developmental milestones. These
findings suggest that late-life restoration of NAD+
levels represents an opportunity to rescue female
reproductive function in mammals.INTRODUCTION
Increasing maternal age and subsequent infertility have rapidly
become a significant challenge to family planning, as a result1670 Cell Reports 30, 1670–1681, February 18, 2020 ª 2020 The Aut
This is an open access article under the CC BY-NC-ND license (http://of the irreversible decline in female fertility in mammals. The
rate-limiting factor for successful pregnancy is oocyte quality,
which significantly declines from late in the third decade of life
in humans (De Vos et al., 2014; Sauer, 2015). Despite the enor-
mous demand, there are no clinically viable strategies to either
preserve or rejuvenate oocyte quality during aging, which is
defined by the capacity of the oocyte to support meiotic matura-
tion, fertilization, and subsequent embryonic development. A
non-invasive, pharmacological treatment to maintain or restore
oocyte quality during aging would alleviate a rate-limiting barrier
to pregnancy with increasing age that has driven demand for as-
sisted reproduction technologies (ARTs) such as in vitro fertiliza-
tion (IVF), which is invasive, carries health risks (Kumar et al.,
2011), is expensive, and has a limited success rate.
Although somatic tissues undergo continual regeneration
through turnover by a self-renewing population of resident pre-
cursor stem cells, oocytes in the ovary are laid down during
in utero development in humans, where they form a finite pool
that does not undergo self-renewal. Oocytes are therefore
highly susceptible to age-related dysfunction. The molecular ba-
sis for the decline in oocyte quality with advancing age impli-
cates genome instability, reduced mitochondrial bioenergetics,
increased reactive oxygen species (ROS), and disturbances dur-
ing meiotic chromosome segregation due to compromised
function of the spindle assembly checkpoint (SAC) surveillance
system (Franasiak et al., 2014; Greaney et al., 2018). The molec-
ular cause of chromosome mis-segregation in oocytes with
advancing age is still unknown, and as a result, there are nohor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
pharmacological strategies to correct this problem. Understand-
ing the molecular or metabolic basis of this defect could lead to
therapies that could maintain or even rescue female fertility with
advancing age.
The metabolite nicotinamide adenine dinucleotide (NAD+/
NADH) is a prominent redox cofactor and enzyme substrate
that is essential to energy metabolism, DNA repair, and epige-
netic homeostasis. Levels of this essential cofactor decline
with age in somatic tissues (Massudi et al., 2012), and reversing
this decline through treatment with metabolic precursors for
NAD+ has gained attention as a treatment for maintaining late-
life health (Mills et al., 2016; Rajman et al., 2018). Here, we
demonstrate that autofluorescence of NADH and its phosphory-
lated form NADPH declines in oocytes with age, and we delin-
eate a role for NAD+ and a potential role for the NAD+-consuming
enzyme SIRT2 as mediators of fertility that are open to pharma-
cological intervention.
RESULTS
We sought to determine whether NAD+ declined in oocytes with
age, contributing to infertility and declining oocyte quality, and
whether this could be reversed through treatment with the
NAD+ precursor nicotinamide mononucleotide (NMN) (Yoshino
et al., 2011). To address these questions, we used mice, whose
fertility starts to decline around 8 months of age due to oocyte
defects that are similar to those in humans (Greaney et al.,
2018). Because of the bioanalytical challenges of measuring
NAD+ levels in individual oocytes, we used hyperspectral micro-
scopy imaging techniques that exploit the autofluorescence of
NADH and NADPH (Dong et al., 2019; Kolenc and Quinn,
2019). Twelve-month-old females were treated with NMN in
drinking water (2 g/L) for 4 weeks, following which mature meta-
phase-II (MII) oocytes were recovered and subjected to multi-
spectral microscopy imaging of autofluorescence to determine
the relative abundances of native fluorophores (Figure 1A).
Consistent with our hypothesis, we found that NAD(P)H levels
declined in oocytes from aged animals, compared with young
(4- to 5-week-old) animals, and NMN treatment increased
NAD(P)H levels in oocytes from aged animals (Figure 1B). We
next sought to determine whether this trend occurred across
the entire ovary, rather than in oocytes alone. Using mass spec-
trometry, we did not observe a decline in whole ovary NAD(H)
levels with age (Figure 1C), suggesting that the oocyte repre-
sents an especially vulnerable subunit of the ovary that is subject
to an age-related decline in NAD+, in contrast to the surrounding
stroma that makes up the bulk of ovarian tissue. Consistent with
data from hyperspectral imaging of individual oocytes, NMN
treatment increased NAD+ levels in the whole ovary, as would
be expected following systemic delivery (Figure 1D).
To test whether addressing the age-related decline in oocyte
NAD+ levels would alter oocyte quality, we treated 14-month-
old females with NMN in drinking water (2 g/L) for 4 weeks,
whereas control animals were maintained on the same drinking
water in the absence of NMN. The effects of this intervention
on oocyte quality were assessed in germinal vesicle (GV)-stage
oocytes collected from the ovaries of pregnant mare’s serum
gonadotropin (PMSG)-stimulated animals, which were maturedin vitro to the MII stage, and immunostained to assess spindle
structure and chromosome alignment. NMN treatment notably
rescued spindle assembly (Figure 2A). Oocyte yield was also
increased in aged animals following ovarian hyperstimulation
of C57BL/6JAusb mice with PMSG and human chorionic gonad-
otrophin (hCG) to obtain MII oocytes from the oviduct and hyper-
stimulation of Swiss albino mice with PMSG alone to obtain
GV-stage cumulus oocyte complexes (COCs) directly from
punctured ovaries (Figures 2B and 2C). To further test the impor-
tance of NAD+ biosynthesis, we obtained transgenic mouse
strains that constitutively overexpress the NAD+ biosynthetic
enzymes NMNAT1 or NMNAT3 (Figures 2D and 2E; Figure S1;
Yahata et al., 2009), which are localized to the nucleus or the
mitochondria, respectively (Berger et al., 2005). These animals
had increased levels of NMNAT1 and NMNAT3 in ovarian tissue,
though these proteins could not be detected in oocytes by west-
ern blot, most likely because of the low protein concentrations
that were obtained from oocytes relevant to other tissues. As
with NMN treatment, 12- to 14-month-old Nmnat1Tg/+ animals,
but not Nmnat3Tg/+ animals, yielded more oocytes than their
wild-type littermates (Figures 2D and 2E), suggesting that the
subcellular localization of NAD+ biosynthesis is important for
follicular and oocyte function. To test the requirement for NAD+
biosynthesis inmeioticmaturation, we treated GV-stage oocytes
with FK866, an inhibitor of the NAD+ biosynthetic enzyme
NAMPT (Hasmann and Schemainda, 2003), and assessed
meiotic progression (Figure S2). Both germinal vesicle break-
down (GVBD) and polar body extrusion (PBE) were slowed by
FK866 treatment, consistent with the idea that NAD+ synthesis
is essential to oocyte function.
Next, we sought to determine whether late-life NMN treatment
resulted in oocytes with improved developmental potential.
Twelve-month-old animals were treated with NMN for 4 weeks
(2 g/L, drinking water), and MII oocytes were collected from
oviducts following PMSG and hCG stimulation. Oocytes from
NMN-treated, aged (12-month-old) animals had a larger diam-
eter (Figure 2F), which may be relevant given that oocytes
with smaller diameters are associated with poorer outcomes
following IVF (Atzmon et al., 2017; Marquard et al., 2011). A
separate cohort of oocytes was subjected to IVF, and at day 6,
the proportion of embryos that reached blastocyst formation
was assessed (Figure 2G), with a trend toward improved blasto-
cyst formation rates.Wenext sought to determinewhether in vivo
NMN treatment would alter subsequent inner cell mass develop-
ment of blastocysts, which is highly predictive of pregnancy suc-
cess (Lane and Gardner, 1997). Twelve-month-old mice were
treated with NMN in drinking water for 2, 7, 14, or 28 days, and
oocytes subjected to IVF. At day 6, embryos were subjected to
differential staining of the inner cell mass. The length of NMN
treatment in animals correlated with improvements in inner cell
mass size (Figure 2H), and to confirm that this translated to
improved fertility outcomes, we treated a cohort of 13-month-
old animals with two different doses of NMN (drinking water,
0.5 and 2 g/L) for 4 weeks before the introduction of a male of
proven fertility. Breeding performance as determined by preg-
nancy, live births, and litter size was then assessed for the
following 9 weeks, from 14–16 months of age (Figures 2I–2M).
NMN treatment improved the time to first live birth (Figure 2J)Cell Reports 30, 1670–1681, February 18, 2020 1671
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Figure 1. Oocyte NAD+ Levels Decline with Age and Are Increased with NMN Treatment
(A and B) Multispectral imaging (A) to determine NAD(P)H content in oocytes from young (4- to 5-week-old) or aged (12-month-old) mice treated with NMN
(drinking water, 2 g/L, 4 weeks) (scale bar is 20 mm), quantified in (B) (one-way ANOVA 1.454 (2, 71), *p = 0.0165, 0.0287 by Dunnett’s multiple comparison test,
n = 21–27 oocytes per group).
(C and D) Mass spectrometry of the whole ovary (C) shows no change in NAD(H) levels between the ages of 1 and 14 months (n = 6 mice per group); however, (D)
NMN increased ovarian NAD(H) in 14-month-old mice (1 h following 400 mg/kg oral gavage, *p = 0.0123, **p = 0.0072, two-tailed t test, n = 20 mice per group).and the overall proportion of animals achieving live birth during
the breeding trial (Figure 2K), though this surprisingly occurred
at the lower dose of NMN (0.5 g/L), suggesting that previous ex-
periments were performed at a dose that benefited oocyte qual-
ity but may have adversely affected other aspects of fertility. This1672 Cell Reports 30, 1670–1681, February 18, 2020could be related to an upper limit to NMN tolerability or the
increased formation of the NMN degradation product nicotin-
amide, which is a sirtuin inhibitor (Bitterman et al., 2002). These
data from orthogonal pharmacological and genetic approaches
show that increasing NAD+ enhances ovulation rate, oocyte
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Figure 2. NMN Treatment Restores Oocyte Quality, Follicle Dynamics, Embryo Development, and Live Birth Rates
(A) NMN treatment (drinking water, 2 g/L, 4 weeks) with NMN from 14 months restores spindle assembly in immunostained oocytes (b-tubulin in green, Hoechst
for DNA in blue, kinetochores in red, p = 0.0503 by Fisher’s exact test, n = 23–25 per group). Disordered spindles with lagging chromosomes are indicated by
arrows, and normal, barrel-shaped bipolar spindles with DNA aligned along the metaphase plate are indicated by arrowheads.
(B and C) Oocyte yield following ovarian stimulation in (B) aged (12-month-old) C57BL/6JAusb mice (*p = 0.0211, two-tailed t-test, n = 29–30 animals per group)
and (C) 14- to 16-month-old Swiss albino mice (Kruskal-Wallis 16.31, ***p = 0.0004, *p = 0.0295 by Dunnett’s mulitple comparison test, n = 4–11 per group).
(legend continued on next page)
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quality, and overall live birth rates in aged female mice, though
they point to an optimum range of dosing.
Given the potential for clinical translation of this work, it was
important to assess whether this treatment would adversely
affect the health or development of offspring following maternal
NMN exposure. Offspring from a separate cohort of animals
maintained on the higher dose of NMN (2 g/L) beforemating, dur-
ing pregnancy, and throughout lactation were maintained on
normal chow or challenged with high-fat feeding to determine
their health and development. Animals were assessed for phys-
iological and behavioral changes (Figure S3). There were no
changes from maternal NMN exposure, except for a small in-
crease in lean body mass from maternal NMN treatment (Fig-
ure S3D). These data are in line with recent work (Ear et al.,
2019) suggesting that administration of theNAD+ precursor nico-
tinamide riboside (NR) during lactation is not harmful and may
improve offspring health.
We next sought to determine the mechanism that mediated
these benefits. One candidate that we hypothesized for this
role is the NAD+-dependent deacylase SIRT2. We previously
showed that SIRT2 stabilizes the SAC protein BubR1 (North
et al., 2014), which is critical for meiotic progression (Homer
et al., 2009), kinetochore attachment, and chromosome segre-
gation in oocytes (Qiu et al., 2018; Touati et al., 2015; Zhang
et al., 2014). Levels of BubR1 decline in mouse reproductive tis-
sue (North et al., 2014) and human oocytes with advancing age
(Riris et al., 2014). SIRT2 maintains genome stability through
deacetylation of Cdc20 and Cdh1 required for sustaining the ac-
tivity of the anaphase-promoting complex (Kim et al., 2011),
which is an essential oocyte regulator (Homer, 2013; Jin et al.,
2010).
To test whether SIRT2 could recapitulate the benefits of NMN
treatment, we obtained a strain of Sirt2Tg/+ mice (North et al.,
2014) that overexpress SIRT2 in all tissues, including oocytes
(Figure S4A), and assessed oocyte quality at the age of
14 months. As with our previous experiments, oocytes were
immunostained to assess spindle structure and chromosome
alignment. As expected, more than 70% of oocytes from repro-
ductively aged wild-type (Sirt2+/+) animals had strikingly disor-
dered spindles and poorly aligned chromosomes (Figures 3A
and 3B), whereas 80% of oocytes from SIRT2 transgenic
(Sirt2Tg/+) littermates exhibited normal barrel-shaped bipolar
spindles and well-aligned chromosomes. Following stimulation
with PMSG, twice as many COCs were obtained from aged(D and E) Aged (12- to 14-month-old) transgenic mice overexpressing NMNAT1 ha
in comparison to transgenics overexpressing NMNAT3 (n = 7–11) (E).
(F) Oocyte diameter following NMN treatment (2 g/L, drinking water, 4 weeks) in
8.504, ***p = 0.0002, *p = 0.0332 by Dunnett’s multiple comparison test, n = 21–
(G) In a parallel cohort, oocytes were used for IVF, with blastocyst formation at d
dependent experiment).
(H) 12-month-old C57BL/6 females were treated for the indicated times with NMN
cell mass was assessed (Kruskal-Wallis 11.93, *p = 0.0337 by Dunn’s multiple com
C57BL/6 females (n = 15–17 per group) were treated for 4 weeks with NMN in drin
and breeding performance was assessed over the next 9 weeks.
(I–M) Breeding performance was assessed by (I) cumulative time to pregnancy, (J
achieving live birth (Fisher’s exact test, *p = 0.0253 ctrl versus 0.5 g/L NMN), (L) c
F(2, 43) = 4.925, p = 0.0119, Dunnett’s multiple comparison ctrl versus NMN 0.5, *
(Kruskal-Wallis 9.220, p = 0.0100, Dunn’s multiple comparison, *p = 0.0491 ctrl v
1674 Cell Reports 30, 1670–1681, February 18, 2020Sirt2Tg/+ ovaries compared with Sirt2+/+ littermates (Figure 3C).
Given the importance of spindle integrity and chromosome
alignment for chromosome segregation, we next tested whether
oocytes from agedSirt2Tg/+ animalsmight be less prone to aneu-
ploidy, a pathogenomic feature of poor-quality oocytes from
aged females. Predictably, aneuploidy rates increased with
age, from 15% at 3 months of age to 43% at 16 months of age
in Sirt2+/+ wild-type oocytes, whereas in oocytes from aged
Sirt2Tg/+ littermates, the incidence was 20%, comparable to
young females (Figure 3D). Oxidative stress is a key driver of
oocyte aging and female infertility (Agarwal et al., 2012). SIRT2
deacetylates and maintains the activity of the pentose phos-
phate pathway enzyme G6PD (Wang et al., 2014), which regen-
erates the antioxidant glutathione through its production of
NADPH. Compared with wild-type oocytes, Sirt2Tg/+ oocytes
from aged animals displayed markedly reduced levels of ROS,
as determined by staining with the ROS-sensitive fluorescent
dye H2DCFDA under both young (5- to 6-month-old) unchal-
lenged (Figures 3E and 3F) and H2O2-challenged conditions
(Figures S4D and S4E). Consistent with these data and our
hypothesis, we observed increased G6PD enzyme activity in
Sirt2Tg/+oocytes (Figure 3G).
Given the improved characteristics of oocytes from aged
Sirt2Tg/+ animals, we sought to determine whether this translated
into improved fertility. Starting at the age of 15 months, animals
were subjected to breeding trials to determine pregnancy rates.
Consistent with very low fertility at this age, only 25% of wild-
type Sirt2+/+ females achieved a pregnancy over 5 mating
rounds, whereas this rate tripled to 75% in Sirt2Tg/+ females (Fig-
ure 3H). These data demonstrate that the NAD+-dependent
deacylase SIRT2 is sufficient to maintain ovarian function and
female fertility during aging.
Although these data suggested that SIRT2 was sufficient to
recapitulate the benefits of NMN to fertility, we next sought to
determine whether SIRT2 was also obligatory for maintaining
normal oocyte function through the use of Sirt2/ knockout an-
imals. Oocytes from whole-body Sirt2/ knockout mice at the
age of 5–6 months displayed normal spindle assembly and
maturation (Figure 3I), indicating that at a younger age at which
NAD+ is replete, SIRT2 is not essential for accurate spindle as-
sembly or that redundancy exists in the role of SIRT2 with other
yet-to-be-identified factors. These in vivo results from Sirt2
knockout animals are in contrast to in vitro studies (Qiu et al.,
2018; Riepsamen et al., 2015; Zhang et al., 2014). Altogether,ve increased oocyte yield (*p = 0.0416, two-tailed t-test, n = 8–10 per group) (D)
aged (12-month-old) or young (4- to 6-week-old) C57BL/6 females (F(2,71) =
27 oocytes per group).
ay 6 of embryo development (each datapoint is cumulative data from one in-
in drinking water (2 g/L), andMII oocytes were subjected to IVF. At day 6, inner
parison test, n = 8–26 oocytes per group). Previously untreated 13-month-old
king water at two doses (0.5 and 2 g/L), following which a male was introduced
) cumulative time to live birth (log-rank test, **p = 0.0059), (K) overall proportion
umulative number of pups born over time (repeated-measures ANOVA, NMN
***p < 0.0001, error bars show SEM), and (M) overall number of pups per female
ersus 0.5 g/L NMN).
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Figure 3. SIRT2 Transgenic Mice Have Improved Oocyte Quality
(A and B) Oocytes from 14-month-old Sirt2Tg/+ C57BL/6 mice were subjected to (A) immunostaining for spindle assembly (b-tubulin in green, Hoechst for DNA in
blue, kinetochores in red). Disordered spindles with lagging chromosomes are indicated by arrows, and normal, barrel-shaped bipolar spindles with DNA aligned
along the metaphase plate are indicated by arrowheads; this is quantified in (B) (p = 0.0131, n = 10–13 oocytes per group, Fisher’s exact test).
(C) Oocyte yield from aged (14-month-old) Sirt2Tg/+ and wild-type Sirt2+/+ littermates (**p = 0.0030, two-tailed t-test, n = 9 animals per group).
(D) Aneuploidy rates in oocytes from young (2-month-old) and aged (16-month-old) Sirt2Tg/+ and Sirt2+/+ littermates (n = 26 young, n = 5–7 aged).
(E–G) Oocytes from Sirt2Tg/+ mice had decreased ROS levels as determined by (E) H2DCFDA staining, quantified in (F) (****p < 0.0001, two-tailed t-test, n = 29
oocytes per group), with (G) increased G6PD enzyme activity (**p = 0.0019, two-tailed t-test, n = 11–13 using 5 pooled oocytes per sample from 4 animals per
group).
(H) Mating trials from 15 months of age to determine cumulative pregnancy rates (p = 0.1319 after 5 mating rounds, n = 8 animals per group, Fisher’s exact test).
(I) Spindle assembly in oocytes from Sirt2/ knockout animals (n = 6, 14 oocytes per group).these data suggest that SIRT2 is sufficient, but not required, to
improve oocyte quality during aging.
Next, we asked whether elevating NAD+ might also benefit
pre-implantation embryo development. To test this, IVF was per-
formed using in vivo matured oocytes from reproductively aged(12-month-old) or young (4-week-old) females. Following IVF,
embryoswere cultured in the presence or absence of NMN. Sup-
plementation with NMN improved blastocyst formation in em-
bryos derived from oocytes from aged females (Figure 4A), but
not in embryos arising from oocytes from young females (FiguresCell Reports 30, 1670–1681, February 18, 2020 1675
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Figure 4. In Vitro NMN Treatment Enhances Embryo Formation
(A) Oocytes from aged (12-month-old) mice were subjected to IVF, and embryos maintained in 1 mM NMN until day 6 of embryo development (paired two-tailed
t test, day 4 *p = 0.0138, day 5 **p = 0.0086, day 6 **p = 0.0014, n = 9 independent experiments).
(B) Treatment with the NAMPT inhibitor FK866 causes embryo death at day 6, which can be rescued by the NAD+ precursors NMN, nicotinic acidmononucleotide
(NaMN), nicotinic acid riboside (NaR), and NR (Kruskal-Wallis 50.65, p < 0.0001, ****p < 0.0001, **p = 0.0048, *p = 0.0197, ***p = 0.0004, **p = 0.0014, *p = 0.0156,
n = 4–21 embryos per group as shown).
(C) Treatment with sirtinol or splitomicin inhibits blastocyst formation (supplemental), with decreased cell count in blastocysts (one-way ANOVA F(6,162) = 22.44,
***p = 0.0002, ****p < 0.0001 by Dunnett’s multiple comparison test, n = 5–67 per group as shown by raw datapoints).
(D) Co-treatment of sirtinol-treated embryos with NMN rescues this reduction (two-way ANOVA F(1,88) sirtinol = 17.66, NMN = 12.59, *p = 0.0360, 0.0374,
****p < 0.0001 by Sidak’s multiple comparison test, n = 22–23 per group).
(E) Treatment with the p53 inhibitor pifithrin rescues cell count and blastocyst formation (supplemental) in embryos treated with sirtinol (pifithrin F(2,392) = 22.37,
sirtinol F(1,392) = 49.81, ****p < 0.0001 by Sidak’s multiple comparison test, n = 72–78 per group).
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S5A and S5B). To further assess whether NMN could rescue em-
bryo development under challenged conditions, embryos from
young animals were maintained in a simple culture medium
that accentuates culture stress and restricts embryo develop-
ment (Li et al., 2012). Consistent with results from aged animals,
the addition of NMN to simple media improved blastocyst cell
number, an indicator of implantation success (Figure S5C).
Mammalian cells have the capacity to generate NAD+ via
several biosynthetic routes and intermediate precursors (Fig-
ure S6; Bieganowski and Brenner, 2004; Nishizuka and Hayaishi,
1963; Okuno and Schwarcz, 1985; Preiss and Handler, 1958a,
1958b). To assess whether NAD+ synthesis via endogenous
NMN production in the recycling pathway plays a role in embryo
development, we cultured embryos in the presence of the
NAMPT inhibitor FK866 (Hasmann and Schemainda, 2003),
which induced blastocyst degeneration on day 6 of culture (Fig-
ureS5D). This could be rescuedbyNMNcotreatment (Figure 4B),
as well as other NAD+ precursors (Figure 4B). In contrast, treat-
ment with the Priess Handler enzyme nicotinic acid phosphori-
bosyltransferase (NaPRT) inhibitor 2-hydroxynicotinic acid
(Piacente et al., 2017) did not affect embryo development (Fig-
ures S5E, S5F, and S6).
We next sought to determine whether NMN treatment medi-
ated benefits via the sirtuins. The small-molecule sirtuin inhibi-
tors sirtinol (Grozinger et al., 2001) and splitomicin (Bedalov
et al., 2001) impaired embryo growth under simple defined
media conditions (Li et al., 2012; Figure 4C; Figure S5G), and
this decline in embryo cell number was partially reversed by
NMN cotreatment (Figure 4D), suggesting that the sirtuins are
not the primary target of NMN in enhancing preimplantation em-
bryo development. This interpretation is clouded by the absence
of data to confirm that sirtinol offered complete inhibition of its
targets, because only partial inhibition could result in some of
the target using increased NAD+ to rescue embryo development.
Given the ability of sirtuin inhibitors to reduce blastocyst qual-
ity, we next sought to determine the pathway through which
these inhibitors restrict embryo growth. The most prominently
studied member of the sirtuins, SIRT1, deacetylates p53 to
inhibit its activity and prevent apoptosis (Cheng et al., 2003;
Vaziri et al., 2001). p53 activity is increased in embryos produced
by IVF compared with in vivo-derived embryos, likely due to
culture stress, and its genetic deletion overcomes the effects
of culture on blastocyst development (Li et al., 2007, 2012). Acti-
vation of p53 is detrimental, because it inhibits proliferation and
induces apoptosis of the inner cell mass, which goes on to form
the developing fetus (Ganeshan et al., 2010, 2017; Kawamura
et al., 2010). We observed that treatment with the p53 inhibitor
pifithrin (Komarov et al., 1999) overcame sirtinol-mediated
reduction in cell number (Figure 4E) and blastocyst development
(Figure S5H), suggesting that p53-dependent hypotrophy is
sirtuin mediated (Peck et al., 2010).
DISCUSSION
There is an ongoing trend across the developed world to defer
pregnancy until later in life, leading to a steady increase in de-
mand for ARTs. Despite maternal age being the greatest clinical
challenge for reproductive medicine, there are no therapeutictreatments to improve oocyte quality. In the current study, we
show that oocyte levels of NAD(P)H decline with age and demon-
strate that NAD+ repletion using NMN restores oocyte quality
and enhances ovulation rate and fertility. Furthermore, supple-
mentation of NMN in embryo culture media reversed the adverse
effects of age on development.
The present study supports thepremise that age-related reduc-
tions in NAD+ availability are a determinant of declining oocyte
quality and female infertility and that pharmacological restoration
of NAD+ opens a therapeutic window for the treatment of age-
related infertility. Several questions remain, including how NMN
treatment would restore oocyte quality in aged animals. One
well-known consequence of poor oocyte quality with advancing
age is chromosome segregation defects, which overwhelmingly
affect the first meiotic division (MI). Indeed, 80%–90% of age-
related embryonic aneuploidy is the consequenceof femaleMI er-
rors (Greaney et al., 2018). The ability to segregate chromosomes
accurately depends upon multiple factors that critically include
proper spindle assembly and surveillance of chromosome segre-
gation by the SAC, which we and others have shown is critical for
preventing aneuploidy in oocytes (Homer et al., 2005). Adequate
expression of key regulatory factors including SAC proteins is
determined during a protracted growth phase that the oocyte un-
dergoes concomitant with follicle development within the ovary; it
is during this growth phase that the oocyte is transcriptionally and
translationally active and stockpiles the reserves required for
oocyte maturation and early embryonic divisions for when both
transcription and translation have shut down (Greaney et al.,
2018). This is a bioenergetically demanding process, and ATP
consumption is maximal in mouse oocytes during the spindle as-
sembly phase in MI (Dalton et al., 2014). In mouse oocytes, this
growth phase lasts 2–3 weeks before ovulation, whereas we
administered NMN for 4 weeks. Although one explanation for
improved oocyte quality could be related to increased atresia of
suboptimal oocytes before ovulation because of improved quality
control mechanisms, we hypothesize that the length of the NMN
treatment period improves overall oocyte quality during this crit-
ical phase of maturation, with no change in overall sorting or qual-
ity control mechanisms, and instead decreases atresia due to
improved oocyte quality. It may be that NAD+ deficiency with
age impedes energy metabolism through its requirement as an
essential redox cofactor; therefore, treatment with NMN during
this critical phase of susceptibility could lower rates of spindle as-
sembly defects and aneuploidy.
Hyperspectral imaging of NADH and NADPH autofluores-
cence revealed a decline in oocyte NAD(P)H levels with age,
whereas mass spectrometry of homogenized, whole ovary did
not reveal an age-related decline in NAD(H) levels. This may be
related to the increased age of oocytes, which in most mammals
are formed during in utero development and do not undergo
turnover in adult life, with these cells being older than surround-
ing somatic cells. It would be ideal to measure NAD(H) levels in
individual oocytes by mass spectrometry as a complementary
technique, because our inability to accurately assay NADmetab-
olites by mass spectrometry at the single-cell level is a limitation
of this study.
One unexpected aspect of this study was that treatment with a
lower dose of NMN resulted in improved functional fertility, asCell Reports 30, 1670–1681, February 18, 2020 1677
assessed by pregnancy and live birth in aged animals. This could
suggest that there is an optimum range for dosing of NAD+ pre-
cursors beyond which other aspects of fertility could be
adversely affected, lowering functional fertility. This will be an
important concern to the clinical translation of this work, espe-
cially given that NAD+ precursors such as NR are freely available
as supplements. Out of caution, we suggest that these supple-
ments should not be taken by women wishing to become preg-
nant until further studies have been completed.
The present study implicates the NAD+ metabolome in regu-
lating ovulation rate. We hypothesize that this change in ovula-
tion results from decreased atresia of follicles during maturation,
during which oocytes exhibit susceptibilities, as described
earlier, rather than change to ovarian reserve. We do not exclude
the possibility that NMN exerts benefits to follicular development
through direct interactions with tissues other than the ovary,
because we delivered NMN through systemic dosing. Further-
more, other tissues may also be susceptible to an age-related
decline in NAD+.
Although NAD+ is a prominent molecule used as a cofactor or
substrate across a range of reactions, we sought to determine
whether the benefits of NMN to oocyte integrity might be medi-
ated partly by the NAD+-dependent deacylase SIRT2. The ben-
efits of in vivo NMN treatment could largely be recapitulated by
transgenic overexpression of Sirt2 in aged animals, although
its constitutive deletion had no adverse impact on oocyte quality,
at least in the younger animals studied here. SIRT2 plays a role
in the maintenance of microtubule-kinetochore attachments
through its deacetylation and stabilization of BubR1 (North
et al., 2014; Qiu et al., 2018), a process that safeguards fidelity
in chromosome separation by ensuring the bipolar orientation
of chromosomes to the spindle. Consequently, in oocytes
from Sirt2Tg/+-overexpressing animals, increases in kineto-
chore-microtubule stability may have contributed to augmented
chromosome alignment and improved fertility. These observa-
tions are in agreement with separate in vitro studies in which
chemical or morpholino-mediated Sirt2 knockdown in oocytes
resulted in severe spindle defects and chromosome disorganiza-
tion (Qiu et al., 2018; Riepsamen et al., 2015). In contrast to those
studies, we observed that oocytes from constitutive Sirt2
knockout mice maintained normal spindle assembly and chro-
mosome organization, suggesting that SIRT2 may be dispens-
able for oocytes. This interpretation is limited by the young age
of knockout animals in that experiment; the only way to defini-
tively determine whether SIRT2 mediates the benefits of NMN
in fertility would be to test NMN treatment in aged (12- to
14-month-old) Sirt2 knockout mice. Another limitation of this
study was that we did not measure ROS or G6PD activity in
oocytes from these knockout animals. These data suggest the
existence of overlapping mechanisms that may compensate
during development. Other members of the sirtuins family have
been implicated in oocyte development (Tatone et al., 2018;
Zhang et al., 2016), and further studies could aim to investigate
whether these members are involved in mediating the benefits
of NMN treatment observed here. Overall, our data do not yet
suggest a role for SIRT2 in mediating the benefits of increased
NAD. Increasing NAD+ levels could instead be affecting oocytes
by simply enhancing energy metabolism.1678 Cell Reports 30, 1670–1681, February 18, 2020Having demonstrated that in vivo NMN treatment in aged an-
imals improved oocyte quality and increased ovulation rate
and birth rates, we next showed that supplementing embryo cul-
turemedia with NMN improved embryo development in embryos
derived from oocytes from aged animals, but not young animals,
supporting the idea that this intervention addresses an age-
related deficit in oocyte NAD+ levels. This finding is highly rele-
vant to the clinical practice of IVF. In addition to age-related
issues of decreased oocyte numbers and oocyte quality, mitotic
aneuploidy (Munne´ et al., 2002) and poor preimplantation em-
bryo development (Janny and Menezo, 1996) limit the number
of euploid blastocysts available for transfer with increasing
maternal age. The increasing preference for blastocyst-stage
transfers in clinical IVF underscores the importance of reaching
more advanced developmental milestones (National Perinatal
Epidemiology and Statistics Unit, 2016) and clinical demand
for interventions that can improve embryo development.
Although this study used NMN as an NAD+ precursor, alterna-
tive precursors from other pathways also raise NAD+, most
notably NR (Trammell et al., 2016). We anticipate that this and
similar compounds will also exhibit efficacy in oocyte quality
and fertility, and it is unlikely that these effects are unique to NMN.
This work represents a clinically tractable pharmacological
intervention to non-invasively treat female infertility caused by
a loss of oocyte viability in reproductively aged females, with
important clinical implications. We envisage this work could
lead to the development of orally delivered therapeutics that
enhance oocyte quality for natural conception or IVF. Moreover,
this work could enhance the success rates of existing IVF proto-
cols by improving embryo culture conditions and developmental
outcomes. Any intervention that improves fertility would lead to
cost savings and lower the emotional stress of failed IVF rounds
or infertility that can lead to long term psychological and social
issues, including depression and relationship breakdown. This
could represent an intervention that enables women with poor
oocyte quality to have children with their own genetic makeup,
because currently, these women have no alternative but to use
donated oocytes. Future studies should aim to test NAD+-raising
compounds in a clinical setting, both as an oral therapeutic and
as an additive to embryo media, to assess the relevance of these
findings to human infertility. While promising, we caution against
the use of NAD+-raising supplements until these clinical studies
have been completed.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Transgenic and wild-type mouse (Mus musculus) strains were bred at Australian Bio-Resources (ABR) in Moss Vale, NSW Australia
and delivered to UNSW Sydney at 6-7 weeks of age. Animals were maintained in individually ventilated cages at 22C at 80% hu-
midity at a density of up to 5 per cage, with ad libitum access to food and water. All water in this animal house was acidified to
pH 3 with HCl to decrease microbial growth. The UNSW animal house maintained a 12 hr light/dark cycle with lights on at 0700
and off at 1900. With the exception of SwissTacAusb mice used in Figure 2C, animals were on the C57BL/6JAusb background.
The ages of animals in each experiment can be found in figure legends. Experiments were carried out with prior approval of the
UNSW Animal Care and Ethics Committee (ACEC) under ACEC numbers 13/134B, 15/134A and 18/133A. UNSW ACEC operates
under animal ethics guidelines from the National Health and Medical Research Council (NHMRC) of Australia. The generation of
SIRT2, NMNAT1 and NMNAT3 transgenic mouse strains used here were as previously described (North et al., 2014; Yahata
et al., 2009).
METHOD DETAILS
Ovarian stimulation, oocyte collection for in vitro maturation and spindle assessment (Figures 1 and 2)
To collect germinal vesicle (GV) stage cumulus oocyte complexes (COCs) for counting and for in vivo maturation for spindle
morphology assessment, both ovaries from eachmouse were recovered 44 to 46 hours after ovarian stimulation with 7.5 IU Pregnant
mare’s serum gonadotropin (PMSG) (MSD Animal Health, Australia), which was administered by intraperitoneal (i.p.) injection. Fat
and tissue surrounding the ovaries was carefully and rapidly removed under the microscope. Oocytes were mechanically released
from ovaries under M2 medium supplemented with 3 mg/ml bovine serum albumin (BSA) in the presence of the growth inhibitor
3-isobutyl-1-methylxanthine (IBMX) (Sigma Aldrich, Australia) at 50 mM using 27-guage needle. The released oocytes, including
cumulus oocyte complexes (COC) and denuded oocytes (DO) in the germinal vehicle (GV) stage were collected by aspirator tubes
(Sigma Aldrich) and transferred into another drop of IBMX-M2 media overlayed with paraffin oil (EMD Millipore corporation, USA),
which was pre-warmed to 37C. Oocytes were then counted, and the cumulus cells removed by mechanical disruption with a mouth
pipette. Oocytes were then rinsed 3 times in IBMX-free M2 (Sigma Aldrich, Australia) containing 3 mg/ml BSA, following 24 hours
pH calibration in 5% CO2, to wash out the IBMX from oocytes, then transferred into another clean, pH calibrated M16 mediumCell Reports 30, 1670–1681.e1–e7, February 18, 2020 e2
that was overlayed with oil and returned to the incubator under 37C in a humidified atmosphere of 5% CO2 to assess subsequent
meiotic development. Meiotic maturation measurements included the rates of germinal vesicle breakdown (GVBD) and first polar
body extrusion (PBE). The rates of GVBD were measured by counting the number of oocytes where there was a disappearance
of nuclear membranes in the first two hours after release. Oocytes that failed to develop into the GVBD stage after 2 hours were
discarded, and the remaining GVBD stage oocytes were then continuously incubated to assess PBE development, indicated by
the production of first polar body, in 14 hours, 16 hours and 20 hours afterward.
For immunofluorescence and spindle analysis, oocytes which had achieved polar body extrusion were removed from culture me-
dium and very briefly washed through PHEM solution (60 mM PIPES at pH 6.9, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2.7H2O),
prior to being pre-permeabilized in 0.25% Triton X-100 (Sigma) in PHEM for 5 s at room temperature to soften the zona pellucida.
Oocytes were then fixed in 3.7% paraformaldehyde (Sigma) in PHEM for 20 minutes before being permeabilized for 10 minutes in
0.25% Triton X-100 in PBS. Oocytes were then washed in PBS containing 0.5%Bovine serum albumin (BSA) (Sigma) (wash solution)
for 5 minutes at room temperature before being blocked overnight in PBS containing 3% BSA and 0.05% Tween-20 (blocking so-
lution) at 4C. The following morning, oocytes were allowed to equilibrate to room temperature and were probed with primary
antibodies.
For immunolabelling, human anti-centromere antibodies (ACA; 1:40; ImmunoVision) and;mouse anti-b-tubulin (1:800; Sigma) were
used to label kinetochores and microtubules, respectively. Following primary antibody incubation, the oocytes were then washed
and placed into the following secondary antibodies: Alexa Fluor 546-labeled goat anti-human (1:200; Invitrogen) for detecting
ACA; and Alexa Fluor 488-labeled goat anti-mouse (1:200; Invitrogen) for detecting b-tubulin. DNAwas labeled using 60 s incubation
in Hoechst 33342 (1 mg/ml; bis-benzimide; Sigma) in PBS at RT. Oocytes were then transferred to 1-2 mL micro-drops of PBS under
mineral oil in glass bottom dishes for confocal imaging.
Serial Z sections of fixed oocytes were captured at 0.5 mm intervals, to span the entire region of the spindle, using an A1MP+multi-
photon confocal microscope (Nikon, Japan) equipped with a C-Apochromat 63x/1.4 NA oil immersion objective, and processed
using NIS-Elements C acquisition and analysis software (Nikon, Japan). Confocal image stacks were projected and further pro-
cessed using the imaging software FIJI.
For spindle analyses, oocytes exhibiting barrel-shaped bipolar spindles with well-organized microtubule fibers, along with tightly
aligned chromosomes on the metaphase plate, were considered as normal. Disordered spindles and lagging chromosomes were
considered as abnormal. In order to blind the investigator to analysis, oocytes were given a color code for each dish for imaging
and scoring, these color codes corresponded to a treatment group that was blinded to the investigator until after imaging and
scoring.
Monastrol treatment and ploidy assessment
Following in-vitro maturation, MII oocytes were cultured for 2 h in M2 medium (Sigma) containing 100 mM monastrol (Sigma), a
kinesin-5 inhibitor used to align chromosomes for investigations of chromosome number and dynamics (Kapoor et al., 2000).
Oocytes were then fixed, blocked and immunostained as described in the above section. Kinetochores were detected using
human anti-centromere primary antibody (ACA; ImmunoVision), followed by incubation in Alexa Fluor 546-labeled goat
anti-human (1:200; Invitrogen). DNA was labeled using 10-minute incubation in a 1:5000 dilution of Sytox Green nucleic acid
stain (Invitrogen). Images were acquired at 0.5 mm intervals using the microscope described above and processed using the
FIJI software.
To obtain a chromosome count in each oocyte, the Z-projection image was initially analyzed to determine the number of
kinetochore pairs. Where there was possible overlap of kinetochores or equivocation, serial confocal sections were analyzed
while carefully noting the orientation of the chromosomes. Oocytes with excessive chromosome clumping and those with
ambiguous counts were excluded from the final aneuploidy assessment. A single trained observer performed all calculations
and ploidy determination. Treatment groups were blinded to the investigator until after ploidy determination, through the
use of a color code that corresponded to a treatment group which was blinded to the investigator until after imaging and
analysis.
Oocyte collection and confocal imaging – DCFDA staining
To collect mature MII COCs, mice were super-ovulated with an intraperitoneal (i.p.) injection of 10 IU pregnant mare serum gonad-
otrophin (Folligon; Intervet, Boxmeer, Holland) to stimulate follicle growth, followed by a 10 IU i.p. injection of human chorionic
gonadotrophin (hCG; Chorulon, MSD Animal Health, Australia) 46 hr later to induce ovulation. COCs were collected form oviductal
ampullae using a 27-guage needle and collected in HEPES-buffered a-minimum essential medium (a-MEM; GIBCO Life Technolo-
gies, Grand Island, NY) supplemented with 3 mg/ml bovine serum albumin (BSA; Sigma Aldrich, St Louis, MO) 14 – 16 h after hCG
injection.
In order to assess the response of the oxidative stress defense mechanisms of oocytes, intra-oocyte glutathione (GSH) and reac-
tive oxygen species (ROS) levels were assessed using the fluorescent probes 5-(and-6)-Chloromethyl-20,7’-dichlorodihydrofluores-
cein diacetate (CM-H2DCFDA) (Invitrogen). In unchallenged oocytes as shown in Figure 1E, as previously described (Li et al.,e3 Cell Reports 30, 1670–1681.e1–e7, February 18, 2020
2016), MII oocytes were mechanically stripped of their cumulus cells prior to staining and imaging. Oocytes were incubated in
HEPES-buffered buffered a-MEM containing 10 mM CM-H2DCFDA for 30 mins at 37
C protected from light. Oocytes were washed
three times in HEPES-buffered a-MEM medium before transfer into a 2 mL drop of HEPES-buffered a-MEM medium, overlayed
with paraffin oil in a glass bottom 35mm confocal dish (MatTek Corp.). Oocytes were imaged immediately under bright field and fluo-
rescence using a Nikon A1+ confocal microscope using a 20X objective at 37C. For H2O2 challenged oocytes as shown in Fig-
ure S1D, GV cumulus oocyte complexes were recovered from PMSG stimulated animals and mechanically denuded, and incubated
overnight in a-MEM with 50 mM IBMX in a 5% CO2 incubator at 37
C. Oocytes were then incubated in HEPES buffered a-MEM with
IBMX with the addition of 25 mM H2O2, then washed three times and allowed to recover in HEPES buffered a-MEM with IBMX for
90 min, and stained for 30 min in HEPES buffered a-MEM with IBMX containing 10 mM DCFDA. Oocytes were then washed and
imaged immediately by confocal microscopy at 37C. ROS-induced cleavage of CM-H2DCFDA to DCF fluorescence was examined
using an excitation and emission wavelength of 488 nm and 520 nm. Images were taken under fixed conditions with respect to laser
energy, signal detection (gain) and pinhole size. Confocal z stacks of 10 mm thickness with 1 mm increments between slices were
recorded at the equatorial plain of the oocytes. Mean relative fluorescence intensities of DCF were measured in a minimum of 25
oocytes per group using ImageJ Fiji software (Schindelin et al., 2012).
IVF and embryo culture
Oocyte developmental competence was evaluated by examining the capacity of oocytes to support preimplantation embryo devel-
opment following in vitro fertilization (IVF). IVF and embryo culture were performed as previously described by Yeo et al. (2008). All IVF
media was purchased from IVF Vet Solutions (Adelaide, Australia). Briefly, following stimulation of females with 5 IU (young) or 10 IU
(aged) PMSG and hCG, COCs were collected form oviductal ampullae using a 27-guage needle and collected in HEPES-buffered
a-minimum essential medium COCs were washed three times in wash media (Research Wash) supplemented with 4mg/ml of
BSA and co-incubated with capacitated sperm in fertilization media supplemented with 4mg/ml of BSA for 4h at 37C with 5%
O2, 6% CO2 and 89% N2. Sperm was recovered from hybrid CBB6F1 males > 12 weeks of age. Presumptive zygotes were washed
three times inwashmedia and then once in cleavagemedia (Research Cleave) supplementedwith 4mg/ml BSA and cultured in drops
over-layeredwithmineral oil at a density of 1 embryo per 2 ml. Fertilization rates and subsequent on-time development were assessed
every 24 hours.
In the case of simple defined media growth conditions (Figures 4C–E, S5C, S5G, and S5H), oocytes were collected as above,
and then maintained in human tubal fluid supplemented with glutamine and EDTA (HTF-GE) media further was supplemented
with 3mg/ml BSA, which is aminimal essential media that does not contain any hormones or trophic ligands (O’Neill, 1997). Embryos
were cultured individually in 10 mL drops to further induce culture stress from diluting autocrine trophic ligands. Embryoswere fixed at
92 hr post-fertilization for cell counting.
G6PD activity
GV oocytes from PMSG stimulated animals were recovered from ovaries and mechanically denuded of the cumulus layer via
mouth pipetting, and collected into 50 mM Tris-HCl pH 7.44 buffer in a volume of 35 mL with 5 oocytes per sample. The oocytes
were lysed following a single freeze-thaw cycle, and spun down at 16,000 g, 4 degrees for 10 minutes to separate cell debris. The
supernatant (34 mL) was subjected to measurement for glucose-6-phosphate dehydrogenase (G6PD) activity, which was deter-
mined as described previously (Tian et al., 1998). Both 6-phosphogluconate dehydrogenase (6PGD) activity and G6PD+6PGD ac-
tivity were measured separately, and endogenous G6PD activity was determined by subtracting the 6PGD activity alone from the
G6PD+6PGD total enzyme activity value. Each reaction mixture consists of 50 mM Tris-HCl, pH 7.44, 2 mM NADP+ and sample in
which G6PD activity was to be measured. Reactions were initiated with the addition of 4 mM G6P + 4 mM 6PGL or 4 mM 6PGL
alone and activity was measured using a spectrophotometer at room temperature, in a total volume of 60 mL in a 384 well
plate. NADPH production was measured at absorbance 340nm every 30 s, and the rate of NADPH synthesis determined as a
unit of AU/hour.
NAD+ measurements
In Figures 1C and 1D, NAD+ andNADHweremeasured bymass spectrometry. Following euthanasia, ovaries were quickly dissected,
fat removed, weighed, and snap frozen in liquid nitrogen, followed by storage at80C. Ovaries were placed in ice-cold 80%meth-
anol, sonicated on ice for 23 30 s, incubated at30C for 20min, and then centrifuged at 14,000 g for 10min at 4C. The supernatant
was collected and spiked with a fixed volume of internal standard mixture (Nicotinamide-d4; b-NADH-d5 diammonium salt; b-NAD-
d4, from Toronto Research Chemicals, Canada) and dried down using vacuum centrifugation. Samples were reconstituted in
100 mM NH4OAc and filtered through a 0.22 mm filter. Metabolites were quantified by LC-MS/MS as described by Bustamante
et al. (2017) with minor modifications. Briefly, metabolites were separated on a Phenomenex NH2 column (150 mm x 2 mm x
3 mm) using a binary solvent gradient consisting of 5 mM NH4OAc (pH 9.5 adjusted with ammonia) and acetonitrile with a flow
rate of 250 ml/min. Metabolites were measured using a using a TSQ Access mass spectrometer (ThermoFisher Scientific, Waltham,
MA). Calibration curves of individual metabolites were constructed using the peak area ratios (peak area of the metabolite divided byCell Reports 30, 1670–1681.e1–e7, February 18, 2020 e4
peak area of the selected internal standard) of each calibrator versus its concentration. Selected internal standards were as follows:
Nicotinamide-d4 for nicotinamide; b-NADH-d5 for NADH; b-NAD-d4 for NAD+. The concentrations of the endogenous metabolites in
the tissue extracts were obtained from these calibration curves. Data were normalized to ovary weight. Spectra were processed and
peak areas integrated using Xcalibur software (version 2.2, 2011, ThermoFisher Scientific). Data processing was performed using the
LCquan feature of the software. Raw datasets are available on our Mendeley site.
The sample size for NAD measurements by mass spectrometry (above) was determined by power calculations based on pilot
results obtained using the previously described NAD+ cycling method of Zhu and Rand (2012). These power calculations, and
the pilot results that informed effect size, are available in the separate Supplemental Information. In these pilot studies, following
euthanasia, ovaries were rapidly dissected out of animals and snap frozen in liquid nitrogen, then stored at 80C. Samples
were then homogenized in NAD+ extraction buffer (10 mM nicotinamide, 50 mM Tris HCl, 0.1% Triton X-100, pH 7.4) by son-
ication. Samples were then centrifuged at 7,000 g for 5 min at 4C to remove insoluble debris. Aliquots were taken for later
protein assay, and samples were then passed through 10 kDa Amicon filters at 14,000 g, 30 min at 4C to remove proteins
from the sample. Flow-through from these samples containing protein-free metabolites were divided into two aliquots. In order
to assess NAD+ alone, in one of these aliquots HCl was added to 10 mM and the samples heated at 70C for 30 min – this step
degrades NADH, leaving behind NAD+. Each sample was measured in technical triplicate, with 25 mL sample added to 100 mL
ADH cycling mix (0.2 mg/ml alcohol dehydrogenase enzyme, 2% ethanol, 100 mM Tris pH 8.5). Samples were allowed to cycle
for 10 min at room temperature, followed by 50 mL addition of an MTT/PMS solution (0.1 mM phenazine methosulfate, 0.8 mM
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), 100 mM Tris-HCl pH 8.5). Plates were then incubated and absor-
bance was measured at 570 nM every 5 min during the cycling reaction, with the 10 min. time point used for the data presented
here. NAD concentrations were extrapolated from a standard curve and normalized to protein concentrations determined by a
BCA protein assay.
Hyperspectral imaging
In this work we utilized a fluorescence microscope adapted for multispectral imaging by adding a number of custom-made fluo-
rescent channels (Gosnell et al., 2016a, 2016b; Habibalahi et al., 2019; Rehman et al., 2017) to characterize native fluorescence
of oocytes. Images were taken in the following channels listed in the table below. We generated a sequence of autofluorescence
images of the same cells in each of these channels at 40 times magnification (40x). To acquire the fluorescence images, a
sensitive camera was used (Prime 95B cMOS from Photometrics). The camera was operated below 65C to reduce sensor-
induced noise.
To prepare spectral images for quantitative analysis and spectral unmixing, first, amultistep image preparation procedure was car-
ried out (Gosnell et al., 2016a, 2016b; Mahbub et al., 2017; Vidal and Amigo, 2012). This procedure removes sources of errors, re-
duces noise and standardizes the spectral images. These steps include (i) image equalization, (ii) denoising, (iii) flattening of back-
ground illumination, and (iv) cell segmentation which was reported in detail in our previous studies (Mahbub et al., 2017). Briefly,
to equalize the images, the intensity value at each channel is converted into the units of photons per pixel per second (PPS). PPS
unite standardizes the images acquired with different acquisition parameters such as camera quantum efficiency and exposure
time. Next, to reduce random noises such as spikes and Poissonian noise, a ‘threshold limiting window’ and wavelet filter were em-
ployed, respectively.
Further, two reference multispectral images including water and calibration were captured using our multispectral microscope
system at the beginning of each experiment. After denoising, the water image was subtracted from the spectral images to remove
the unavoidable autofluorescence signals from the microscope slide, Petri dishes, dirt on sensors etc which forms an additive au-
tofluorescence background contribution to all spectral images. The microscope was calibrated using a fluorimeter (FluoroMax
Plus-C, Horiba). To this aim we used the calibration fluid which is a mixture of 30 mM NADH (quantum yield 0.019) and 5mM ribo-
flavin (quantum yield 0.24) with non-zero fluorescent response across all our spectral channels. The fluorescence spectrum of this
fluid is measured using a fluorimeter and imaged on the multispectral microscope in all our spectral channels. The fluorescence
images of the calibration fluid were then smoothed and associated random noises were minimized. The smoothed spectral images
with subtracted water background, were then divided by the calibration fluid image and multiplied by fluorescence response of the
calibration fluid measured by fluorometer. This was done on a channel by channel basis. Finally, to perform the unmixing process
at a single cell resolution, the cells were isolated manually (segmented) by using their DIC image superimposed on selected auto-
fluorescence images.
In the unmixing process the measured spectral characteristics of the cells were compared to the reference spectra of specific flu-
orophores to find their abundance. In this study, unmixing was performed sing a linear mixing model (LMM). The LMM describes the
fluorescent signal of each pixel is a linear combination of a fraction of endmember component spectra. LMM defines weights asso-
ciated with the concentration of the molecules corresponding to these component spectra. These concentrations were presented as
abundance fractions (Keshava, 2003; Keshava et al., 2000; Keshava and Mustard, 2002) and the Robust Dependent Component
Analysis (Mahbub et al., 2017) (RoDECA) algorithm (available at our Mendeley site) was employed to identify the dominant native flu-
orophores and calculate their relative abundance. All raw datasets are available on our Mendeley site.e5 Cell Reports 30, 1670–1681.e1–e7, February 18, 2020
Spectral channel
Excitation
wavelength (nm)
Emission wavelength
(bandwidth) (nm)
Dichroic mirror
long pass (nm)
Power at
objective(mW)
Exposure
time (s)
1 345 ± 5 414 (46) 389 6.0 10
2 345 ± 5 451 (106) 389 6.2 6
3 345 ± 5 575 (59) 552 5.7 10
4 358 ± 5 414 (46) 389 5.2 10
5 371 ± 5 414 (46) 389 6.8 10
6 358 ± 5 451 (106) 389 5.2 10
7 371 ± 5 451 (106) 389 6.9 10
8 358 ± 5 575 (59) 552 6.3 10
9 371 ± 5 575 (59) 552 9.9 10
10 377 ± 5 575 (59) 552 18.6 10
11 437 ± 5 575 (59) 552 28.8 10
12 457 ± 5 575 (59) 552 25.2 10
13 476 ± 5 575 (59) 552 24.1 10
14 358 ± 5 594 (long-pass) 552 6.7 10
15 371 ± 5 594 (long-pass) 552 10.4 10
Spectral specification of channels used in this studyHigh fat feeding
Animals were maintained on chow or high fat diets as described previously (Wu et al., 2014). Chow diet (Gordon’s Specialty Stock
Feeds, Yanderra, New South Wales, Australia) comprised 8% calories from fat, 21% calories from protein, and 71% calories from
carbohydrate, with total energy density of 2.6 kcal/g. High-fat diet (HFD) was prepared in-house and comprised 45% calories
from fat (beef lard), 20% calories from protein, and 35% calories from carbohydrate at a density of 4.7 kcal/g, based on rodent
diet D12451 (Research Diets, New Brunswick, NJ, USA).
Offspring studies
Male offspring from the control and NMN only treated groups of the breeding trials shown in Figure 3A were maintained to determine
whether maternal NMN exposure adversely impacted offspring health. NMN exposure in the mothers was ongoing in drinking water
(2 g/L) from 16 weeks of age, including during mating, pregnancy and lactation. Offspring were weaned onto normal drinking water
without NMN, and either standard chow diet or high fat diet. Animals were subjected to body composition analysis and glucose toler-
ance testing at 10 weeks of age, and behavioral analyses at 5 months of age.
Sucrose Preference Test (SPT)
Sucrose Preference Test is a standard test for assessing anhedonic behavior, a symptom of depression. This test was performed at
5 months of age in male offspring of NMN treated females according to a previous study with somemodifications (Maniam and Mor-
ris, 2010). Mice were housed individually in separate cages with access to two bottles. Mice were first pre-exposed to sucrose so-
lution (1%, w/v) for 24 h as a training to adapt to the newly introduced sucrose solution. They were given access to 2 bottles (sucrose
1%, tap water). On the second day, food and water were removed for 6 hours before being giving access again to sucrose and water.
In order to avoid place preference, the position of the bottles was changed, and mice were given to both 1% sucrose solution
and water for 24 h. Sucrose preference was calculated according to the following formula: sucrose preference (%) = sucrose intake
(g) / [sucrose intake (g) + water (g)] x 100%
Light/Dark Test
The light/dark test (LDT) is a standard test to assess anxiety-like behavior. This test was conducted during light phase at 5 months of
age according to a previous protocol (Maniam andMorris, 2010). The LDT apparatus comprised of bright and dark perspex compart-
ments (24 cm 24 cm 27 cm) connected by a small opening (10 cm 10 cm). The light reading on the floor of the light area was
4000–5000 lux and the dark area was lit between 1 and 10 lux. Mice were gently placed in the light area, facing away from the
doorway. The total time spent in light and dark areas were recorded for 5 min. The percentage of time spent in light was calculated
using the following formula: % time in light area = time spent in light /[(time spent in dark + time spent in light)].
Glucose tolerance test (GTT)
GTT was as described previously (Wu et al., 2014). Animals were fasted from 0800 on the day of the test. At 1400, baseline blood
glucose was assayed using a hand-held glucose testing meter (Accu-Check, Roche) through a scalpel nick less than 1 mm from
the tip of the tail, with tails protruding from a small upturned cardboard box used to calm animals. Animals were injected with
25% glucose (i.p. injection) at 2 g/L lean body mass, and glucose was assessed at indicated time points from tail bloods. Lean
body mass was assessed by quantitative MRI.
Body composition measurements
Body composition was determined by quantitative MRI using an echoMRI (Houston, TX USA) in conscious animals.Cell Reports 30, 1670–1681.e1–e7, February 18, 2020 e6
Oral gavage and pharmacodynamics
Animals were administered a single oral gavage of NMN in a volume of 100 mLwater per 20 g bodymass for a total dose of 500mg/kg.
Animals were euthanased at the indicated time point, and ovaries rapidly dissected, cleared of surrounding adipose tissue, and snap
frozen for subsequent analysis of NAD+ levels.
Breeding trial design
The reproductive capacity of 16-month old SIRT2-Tg mice (n = 8) were compared to that of age-matched wild-type littermates (n = 8).
We employed a timed-mating protocol, whereby each breeding round commenced with group-housed female mice being ‘scented’
using dirty bedding fromamale’s cage for 3 days. This design allowed for stimulation and synchronization of the females’ estrous cycles
through theWhitten Effect (Jemiolo et al., 1986). Each femalewas thenplaced into an individually-housed provenmale breeder’s cage in
a 1:1 ratio (‘co-habitation’). This transfer was made in the evening, in anticipation of night-time ovulation (2). The animal-holding facility
default light setting is a 12-hour light/12-hour dark cycle. The following earlymorning each femalewould beassessed for the presenceof
viscous vaginal plug as evidence of copulation and, regardless of plug status, were separated to prevent daytimemating. Females with
no plug would be replaced with the same male the following evening to undergo another night of mating. If, following 3 consecutive
nights of co-habitation, no plug had been observed, females would be separated and observed for weight gain for 5 days to account
for the possibility of missed plugs, before undergoing re-scenting. A female would repeat the current mating round until a positive plug
was confirmed. Females with positive plug were considered to have passed that mating round and would be housed separately before
undergoing micro-ultrasound (VisualSonics Vevo 2100 Ultrasound) on day 15 post-copulation (pc) to determine pregnancy state, as
determined by the presence of a fetal heartbeat. Females that had copulated, as demonstrated by plug presence, but did not fall preg-
nant would be deemed to have failed that mating round and would commence the next mating round with a different male stud, and so
on. The scheme for this experiment is shown in Supplemental Information (Methods S1). The data presented in Figure 3H show the
cumulative rate of pregnancy following confirmation of mating as described above.
Taking into account the high prevalence of labor difficulty and maternal cannibalism that was encountered in aged nulliparous
mice, we were unable to determine offspring number from each pregnancy in the aged Sirt2 transgenic cohort.
The breeding trial for NMN treated animals as presented in Figure 2J used a different protocol. In this experiment, untreated
12 month old ex-breeder females were treated with NMN (drinking water, 0.5 or 2 g/L) for 4 weeks, following which a male of proven
fertility was introduced on an ongoing basis. Animals were weighed weekly, with weight gain of 5 g indicative of pregnancy. Once
noted as pregnant, animals were monitored daily for live births. The date of live birth and number of pups were recorded, following
which pups were removed and themale re-introduced for further breeding. The cumulative proportion of animals achieving live births
was used as the primary outcome for this study, which lasted for 9 weeks following the introduction of males. NMN treatment
continued throughout the breeding trial phase of the study.
QUANTIFICATION AND STATISTICAL ANALYSIS
Prior to conducting studies, power calculations were performed to determine sample size using G*Power 3.1, based on effect sizes
observed in preliminary pilot studies.
For all continuous outcomes, datasets were subjected to the D’Augusto & Pearson normality omnibus test. If all groups passed this
test, data were analyzed as either a two-tailed Student’s t test (2 groups), ANOVA (3 or more groups) or as a two-way ANOVA with a
2x2 study design, between group comparisons made by Tukey’s multiple comparison test, as indicated in the text of figure legends.
Non-parametric datasets were analyzed by a two-tailed Mann-Whitney U-test (2 groups) or a Kruskal-Wallis test (3 or more groups)
with between group comparisons made by Dunn’s multiple comparison test. Data were subjected to outlier detection using the
ROUT test (Q = 1% as cut-off) prior to analyses. For datasets with binary outcomes, a two-sided Fisher’s exact test was used.
All statistical calculations and raw datasets are available on our Mendeley site as .xml files (https://doi.org/10.17632/f27ktnj354.1).
All continuous outcome data are presented as violin plots with median and quartile values indicated by dotted lines.
Statistical analyses were performed using GraphPad Prism version 8.1.2.
DATA AND CODE AVAILABILITY
The datasets and code generated during this study are available at a Mendeley site associated with this paper (https://doi.org/10.
17632/f27ktnj354.1). All quantitative datasets have been uploaded to our Mendeley site as .xml files exported from Graphpad Prism.
These files include the details and results of associated statistical analysis as described in the previous section. Un-cropped western
blots and microscopy images have also been uploaded to this site. Raw data associated with hyperspectral imaging have been up-
loaded with an associated ‘‘read me’’ file, with summarized readings from each channel for each image also shown as a separate
excel spreadsheet. The code used to interpret these data using the RoDECA (Robust Dependent Component Analysis) method
have been uploaded as pseudocode.
ADDITIONAL RESOURCES
There are no additional resources associated with this study.e7 Cell Reports 30, 1670–1681.e1–e7, February 18, 2020
